Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3355 |
|
| Actual shortage: | 217 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ALLOPURINOL | 200MG | TABLET | Resolved | 2022-12-02 | 2023-01-26 | 176942 |
| APO-ALLOPURINOL | 200MG | TABLET | Resolved | 2022-12-09 | 2023-01-26 | 177615 |
| APO-ALLOPURINOL | 200MG | TABLET | Resolved | 2020-08-19 | 2021-05-17 | 122465 |
| APO-ALLOPURINOL | 200MG | TABLET | Resolved | 2020-08-19 | 2021-05-17 | 122468 |
| APO-ALLOPURINOL | 100MG | TABLET | Resolved | 2020-10-28 | 2021-05-10 | 127328 |
| APO-ALLOPURINOL | 100MG | TABLET | Resolved | 2021-02-19 | 2021-05-10 | 134427 |
| APO-ALLOPURINOL TABLETS | 300MG | TABLET | Resolved | 2024-11-15 | 2024-11-29 | 243187 |
| APO-ALMOTRIPTAN | 12.5MG | TABLET | Resolved | 2017-03-10 | 2019-05-14 | 24 |
| APO-ALMOTRIPTAN | 6.25MG | TABLET | Resolved | 2017-03-10 | 2019-05-14 | 27 |
| APO-ALPRAZ | 1MG | TABLET | Resolved | 2018-04-16 | 2018-10-15 | 46015 |
| APO-ALPRAZ | .5MG | TABLET | Resolved | 2018-05-02 | 2018-11-02 | 47950 |
| APO-ALPRAZ | 0.25MG | TABLET | Resolved | 2018-07-04 | 2018-10-12 | 54165 |
| APO-ALPRAZ | 0.25MG | TABLET | Resolved | 2018-12-27 | 2019-09-16 | 70520 |
| APO-ALPRAZ | .5MG | TABLET | Resolved | 2019-03-05 | 2019-09-05 | 77869 |
| APO-ALPRAZ | .5MG | TABLET | Resolved | 2019-03-06 | 2019-09-09 | 77974 |
| APO-ALPRAZ | 0.25MG | TABLET | Resolved | 2019-03-20 | 2019-09-16 | 79036 |
| APO-ALPRAZ | 1MG | TABLET | Resolved | 2019-04-24 | 2019-08-02 | 82331 |
| APO-ALPRAZ | .5MG | TABLET | Resolved | 2019-09-09 | 2019-09-16 | 93262 |
| APO-ALPRAZ | 0.5MG | TABLET | Resolved | 2024-03-27 | 2024-05-03 | 223546 |
| APO-ALPRAZ | 0.5MG | TABLET | Resolved | 2024-08-01 | 2024-09-27 | 234286 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |